RNA Insider Steven George Executes 10b5-1 Plan: 2,208 Shares Exercised and Sold

Rhea-AI Filing Summary

Avidity Biosciences insider Steven George, the company's Chief Medical Officer, reported option exercises and a contemporaneous sale on 09/22/2025 under a previously adopted Rule 10b5-1 trading plan. He exercised a stock option with a $10.16 exercise price for 2,208 shares, increasing his underlying option holdings by 2,208 shares exercisable through 01/19/2034 and resulting in total beneficial ownership of 70,667 shares. Simultaneously, 2,208 common shares were sold at $40.58, leaving him with 41,075 shares owned directly after the transactions. The filing states the 10b5-1 plan was adopted on 06/12/2024 and the option grant date was 01/20/2024.

Positive

• Transactions executed under a Rule 10b5-1 plan, indicating pre-planned trades and increased transparency.
• Clear disclosure of option grant, vesting schedule, and resulting beneficial ownership, aiding investor understanding.

Negative

• Insider sold 2,208 shares at $40.58, reducing direct holdings to 41,075 shares.
• Exercise and sale indicate insider liquidity, which some investors may interpret unfavorably despite 10b5-1 protections.

Insights

Financial Analyst

TL;DR: Insider exercised and sold equal shares under a 10b5-1 plan; routine liquidity action with limited immediate valuation signal.

The reporting shows a coordinated exercise and sale of 2,208 shares at an exercise price of $10.16 and a sale price of $40.58, executed under a 10b5-1 plan adopted 06/12/2024. Such transactions commonly reflect planned liquidity rather than ad-hoc insider trading. The resultant direct beneficial ownership figures—41,075 shares held after sale and 70,667 shares beneficially owned including unexercised options—are clearly disclosed, supporting transparency for market participants.

Corporate Governance Expert

TL;DR: Use of a documented 10b5-1 plan and clear disclosure aligns with governance best practices.

The Form 4 indicates the transactions were effected pursuant to a Rule 10b5-1 trading plan adopted 06/12/2024 and were signed by an attorney-in-fact on 09/23/2025. The filing includes the grant and vesting terms for the option (grant date 01/20/2024; monthly vesting through 01/20/2028), which enhances clarity about the insider's equity incentives and timing. From a governance standpoint, documented pre-arranged trades reduce concerns about opportunistic timing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hughes Steven George

(Last) (First) (Middle)

C/O AVIDITY BIOSCIENCES, INC.

3020 CALLAN RD.

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Avidity Biosciences, Inc. [ RNA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/22/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/22/2025		M(1)		2,208	A	$10.16	41,075	D
Common Stock	09/22/2025		S(1)		2,208	D	$40.58	38,867	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$10.16	09/22/2025		M(1)			2,208	(2)	01/19/2034	Common Stock	2,208	$0	70,667	D

Explanation of Responses:

1. The exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 12, 2024.

2. This option was granted on January 20, 2024 and vests in equal installments of 2,208 shares on each monthly anniversary of such grant date, until it is fully vested and exercisable on January 20, 2028.

Remarks:

	/s/ John B. Moriarty, Jr., J.D., Attorney-in-Fact	09/23/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did Steven George report on the Form 4 for RNA?

The filing reports an exercise of 2,208 option shares at an exercise price of $10.16 and a sale of 2,208 common shares at $40.58 on 09/22/2025.

Were the trades executed under a 10b5-1 plan?

Yes. The filing states the exercises and sales were effected pursuant to a Rule 10b5-1 trading plan adopted on 06/12/2024.

How many shares does the reporting person beneficially own after the transactions?

The Form 4 discloses 41,075 shares owned directly following the reported transactions and 70,667 shares beneficially owned including options.

What are the option grant and vesting details disclosed?

The option was granted on 01/20/2024 and vests in equal monthly installments of 2,208 shares until fully vested on 01/20/2028.

Who signed the Form 4 submission?

The Form 4 was signed by John B. Moriarty, Jr., J.D., Attorney-in-Fact on 09/23/2025.